ORI-A-ce001

**ORI-A-ce001** is a therapeutic **vaccine** candidate for **acne vulgaris** based on recombinant proteins[5][7][9]. It is administered as an intramuscular injection and developed to stimulate the immune system against *Cutibacterium acnes* (C. acnes), the bacterium most associated with acne lesions. Its proposed mechanism involves **immunostimulant activity**, triggering an antibody response to bacterial virulence factors to reduce inflammation and lesion count[5][7]. The technology is novel: no effective preventative/cure exists for acne, and most treatments for this widespread condition have changed little in decades[1][3][7]. Initial human studies focus on safety, tolerability, immunogenicity (antibody generation), impact on lesion counts, acne severity, and effects on the skin microbiome[1][3].

Brand names

ORI-A-ce001ORI-A-ce-001ORI-A-ce 001Acne vulgaris vaccine - Origimm

Other names

ORI-A-ce001ORI-A-ce-001ORI-A-ce 001ORG101ORG-101ORG 101ORI-001ORI001ORI 001